{"id":49848,"date":"2023-06-30T11:16:18","date_gmt":"2023-06-30T11:16:18","guid":{"rendered":"https:\/\/biomedpharmajournal.org\/?p=49848"},"modified":"2023-07-11T06:02:42","modified_gmt":"2023-07-11T06:02:42","slug":"pathophysiology-clinical-implications-and-management-of-orofacial-neuropathic-pain-with-special-attention-to-trigeminal-neuralgia-a-narrative-review","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol16no2\/pathophysiology-clinical-implications-and-management-of-orofacial-neuropathic-pain-with-special-attention-to-trigeminal-neuralgia-a-narrative-review\/","title":{"rendered":"Pathophysiology, Clinical Implications and Management of Orofacial Neuropathic Pain- with Special Attention to Trigeminal Neuralgia: A Narrative Review"},"content":{"rendered":"\n

Introduction\n<\/strong><\/p>\n\n\n\n

When a peripheral nerve is destroyed,\ninjured nerve fibres produce high-frequency injury discharges. These\nhigh-frequency unfavourable discharges in primary afferent neurons increase the\namount of nociceptive neurons in the spinal dorsal horn, which are then sent to\nthe important frightened machine through dorsal root ganglion neurons 1<\/sup>. Chronic,\nexcruciating pain in the orofacial region is caused by negative discharges from\ntrigeminal ganglion (TG) neurons in the trigeminal system being received by the\nupper cervical spinal cord (C1-C2) and the trigeminal spinal subnucleus\ncaudalis (Vc) 2<\/sup>. At the same time as nociceptive TG, Vc, and C1-C2\nneurons are becoming hyperactive, non-neuronal glial cells and macrophages are\nbecoming activated and accumulating in these areas. Increased macrophage\nawareness and activation of non-neuronal glial cells are assumed to be supplied\nby neuron-non-neuronal cellular interaction, which also complements the\nactivity of neuronal cells 3<\/sup>. . It is  known fact that activated satellite tv for\npheochromocytoma cells (PC cells), microglial cells and accumulating macrophages in the Vc\nand C1-C2 regions release a variety of cytokines, neurotrophic factors, and\ntumour necrosis factors 4, 5<\/sup>. These interactions between neurons and\nnon-neuronal cells thought to enhance the spread of neuronal activity\nthroughout the TG, ventral C Vc, and C1-C2 regions 6<\/sup>.\n<\/p>\n\n\n\n

In addition, the interaction between\nastrocytes and microglia within the C1-C2 and Vc areas is thought to promote\nthe spread of the excitability of nociceptive neurons 7<\/sup>. Neurons in\nthe brain stem convey additional negative data to locations higher up in the\ncentral nervous system 8,9<\/sup>. Recent investigations have shown that\ninjury to the trigeminal nerve alters the manner in which these ascending\nroutes work. In this investigation, we investigate fresh data from animal\nstudies on the properties of materials associated to neuron-non-neuronal\ncellular communication. In addition, we discuss the role that ascending pain\npathways may play in the interpretation of orofacial pathological pain brought\non by injury to the trigeminal nerve. In addition, we provide the clinical\nresults of patients who have trigeminal neuralgia and orofacial neuropathic\npain, as well as their clinical approaches to diagnosing and treating patients\nwho have trigeminal neuralgia.<\/p>\n\n\n\n

Orofacial Neuropathic Pain Peripheral\nMethods<\/strong><\/p>\n\n\n\n

Damage to the trigeminal nerve may cause a\nvariety of painful pain reactions, including persistent orofacial pain,\nallodynia, and hyperalgesia. These phrases are used to characterise the types\nof pain allergy reactions that might occur 5<\/sup>. When peripheral nerves\nare damaged, a cellular response may be triggered by a number of substances\nthat are present at the location of the lesion. An alternative inside the\nimmune cells environment first sets off the cascade of events that leads to the\ninflammatory response that occurs when peripheral nerves are wounded 9<\/sup>.\nDamaged neurons and Schwann cells secrete inflammatory chemicals, which causes\nthe peripheral nerve to become hypersensitive at the same time as immune cells\ninfiltrate the area of the lesion. This makes it possible for the peripheral nerve\nto become hypersensitive 10<\/sup>. In addition, the injured neurons show\nchanges in their neuronal excitability, such as a lower threshold and more\nspontaneous firing 11<\/sup>. To put that into perspective, proinflammatory\nmediators such as tumour necrosis factor-alpha (TNF) and nerve growth factor\nare found in higher amounts near the locations of peripheral nerve damage 12<\/sup>.\nTNF-induced neuronal hyperexcitation is due to the upregulation of\nvoltage-gated sodium channels’ excitatory potential via the activation of\nprotein kinase C. According to Leo et al.’s research from 2015, the binding\nlocation for TNF is the TNF receptor, also known as TNFR, which may be present in\nhealthy nerve terminals 13<\/sup>.<\/p>\n\n\n\n

Due to more appropriate artemin\nsignalling, TRPV1 is overexpressed in tongue nociceptors. This enhances heat\nhypersensitivity response inside the tongue via the activation of p38\nmitogen-activated protein kinase 14<\/sup>. In the aftermath of a lesion to\na peripheral nerve, it is well knowledge that a diverse population of\nmacrophages originating from monocytes will enter the affected area. This\nblood-borne macrophage buildup, which takes place specifically near wounded\naxons, is caused by monocyte chemoattractant protein-1 (MCP-1) signalling,\nwhich determines the course of neuropathy15<\/sup>. It has been cautioned\nthat damaged to peripheral nerves leads to consequences of macrophage\ninfiltration and recruitment to the injury site, which in turn releases\ninsulin-like boom aspect-1 (IGF-1).IGF-1which is launched by way of the\nmacrophages on the web site of nerve injury, communicates with Transient\nReceptor Potential Vanilloid (TRPV2) to inspire\nTransient Receptor Potential Vanilloid (TRPV4) manufacturing in the TG\nneurons that innervate the facial skin. 16] <\/sup>As an end result, the\npores and skin on the face turns into routinely sensitive following peripheral nerve harm, the broken axons, the\nencroaching macrophages, and the Schwann cells all release materials that\nstimulate non-injured axons. It\u2019s miles viable that stimulation of axons that\naren’t broken is what reasons the peripheral neuronal hyper-excitability this\nis so carefully related to neuropathic pain  17<\/sup>.<\/p>\n\n\n\n

Trans-cellular Interaction with both\nInflammatory Cells and Neurons in TG<\/strong><\/p>\n\n\n\n

It is well knowledge that the TG harbours\nprimary afferent neuron somata and that lymphocytes, macrophages, and satellite\nglial cells, all of which communicate with one another via the use of\nneurotransmitters, surround the sensory neuronal soma 8<\/sup>. According\nto the findings of recent study, nerve damage may trigger mobile-to-mobile\ncommunication in TG by utilising humoral chemicals like as cytokines,\nneuropeptides, and fuel. It is quite interesting to look at how macrophages\ncluster together in the TG, which contains the somata of the wounded primary\nafferent neurons and the area of peripheral nerve injury 17<\/sup>. Cells\nthat cause inflammation, such as macrophages, are able to enter damaged\ntrigeminal nerves and then cause a more rapid inflammatory response. In a\nvariety of orofacial clinical circumstances, both invading and resident\nmacrophages experience certain morphological changes, such as thicker\nramifications and a bigger soma, that speed up the release of a variety of\nneurotransmitters 10<\/sup>. Consequently, changes in morphological\nappearance are assumed to indicate that macrophages have been active. In\naddition, macrophages may be subdivided into two distinct histological types\nbased solely on the distinct tasks that they provide in the body. During the\nfirst phases of an anti-inflammatory response, a significant amount of reliance\nis placed on the M1 macrophage. The M1 macrophage is a classically activated\nphenotype that is responsible for the production of a variety of pro\nanti-inflammatory mediators. The M2 macrophage is the second kind, and it is an\nalternatively activated phenotype of macrophage. These macrophages produce a\nrange of proinflammatory mediators, and their features and linkages to tissue\nhealing are discussed below 8<\/sup>. <\/p>\n\n\n\n

The TG is able to govern the excitability\nof TG neurons by means of trans-cell communication between neurons and\nmacrophages via the use of a variety of biochemical mediators 19<\/sup>. Following\nan injury, macrophages migrate into the trigeminal nerve and begin releasing\nTNF into the TG. According to the previous studies 5,18-21<\/sup>\nthe aetiology of orofacial neuropathic pain is a TNF signalling\nconsequence known as a neuronal hypersensitive response in the trigeminal\nganglion. <\/p>\n\n\n\n

Inter-Satellite Cell Communication in Trigeminal ganglion<\/strong><\/p>\n\n\n\n

Recent research has shown that the primary\ncause of neuronal hyperactivity is morphological and functional changes in\nsatellite cells, which are brought on by peripheral nerve damage. These changes\ninclude enlargement of the soma and shortness of the techniques. In addition,\nsatellite cells are able to interact with one another via the use of gap\njunctions, which make it possible for a wide variety of chemicals to move\nfreely across cells 22<\/sup>. According to research by Kaji et al. (2016),\nthe damage of the inferior alveolar nerve in TG leads to morphological\nabnormalities in satellite glial cells. These abnormalities are the primary\ncause of increased orofacial mechanical allergy. These results suggest that\nCx43 causes activation of satellite to for pc glial cells in the TG, hence\nincreasing the trigeminal neuronal excitability and serving as a significant\ncontribution to ectopic orofacial pain. Therefore, ectopic or extraterritorial\npain hypersensitivity, which is caused by non-neuronal mobile methods inside\nthe TG, might be the consequence of peripheral nerve injury within the\norofacial area. Orofacial ectopic pain is a common condition that is often\nmisdiagnosed as dental pain. This error in diagnosis may lead to unnecessary\nand irreversible dental procedures such as pulpotomies and tooth extractions.\nIn addition, knowledge of these processes may significantly help in the\nmanagement of orofacial neuropathic pain and prevent the patient from receiving\nan incorrect diagnosis from a medical professional who is treating orofacial\nneuropathic ache 18<\/sup>.<\/p>\n\n\n\n

M<\/strong>echanisms\nof the Brainstem and Cervical Spinal Cord<\/strong><\/p>\n\n\n\n

The trigeminal spinal nucleus is an\nintensive shape made from the caudalis, interpolaris, and oralis subnuclei. Vc\nshares a layered structure with the spinal cord and takes up most of the\ntrigeminal spinal nucleus. The Vc and the C1-C2 acquire nociceptive enter from\nthe craniofacial location thru primary afferent fibres with somata in TG.\nProjective neurons inside the trigeminal nerve’s branches convey nociceptive\ninformation from the craniofacial area 23<\/sup>.<\/p>\n\n\n\n

The higher CNS areas still have the\nability to get poor signals from the neurons of the brainstem. The MT, the PBN,\nand the posterior medial thalamic nucleus are three essential parts of the CNS\nthat are responsible for orofacial pathological pain and receive noxious inputs\nfrom the Vc and C1-C2 regions 24<\/sup> . It is believed that the orofacial\nnoxious route that projects to ventral posterior medial (VPM) is responsible for mediating the sensory\ndiscriminative aspect of pain. On the other hand, it is considered that the MT\nand PBN pathways have an influence at the motivational and emotional elements\nof aching 24<\/sup>. This theory was presented in a study that was\npublished in 2021. These ascending routes have recently undergone some\npractical alterations as a result of damage to the trigeminal nerve 23,25<\/sup>.\n According to the findings of an\nincreasing number of research conducted in recent years, the glial cells of the\ncentral anxious system play an essential role in initiating an extension of\nalterations in neuronal interest in the Vc after injury has been caused to the\ntrigeminal nerve. Microglia and astrocytes, two of the most important\ncontributors to neuropathic pain, become active when there is irritation in the\norofacial region or injury to the trigeminal nerve 26<\/sup>.<\/p>\n\n\n\n

It is well accepted information that\nmicroglia become activated during the early stages of nerve damage, which may\nbe recognised as astrocytic activation. The immune cells known as microglia,\nwhich are similar to macrophages, are responsible for the production of a\nnumber of proinflammatory cytokines. Some examples of these cytokines include\ninterleukin (IL)-1, IL-6, and TNF. IL-1 is one of these cytokines, and it is\nthe one that phosphorylates N-methyl-D-aspartate (NMDA) receptors in order to\naccomplish its goals 27,28<\/sup> . Mind-derived neurotrophic factor, or\nBDNF for short, is an additional microglial secretory factor that plays an\nimportant role in neuropathic pain. During the time when BDNF is binding to\ntropomyosin-associated kinase B (TrkB), the expression of the k+-Cl-\ncotransporter, potassium chloride cotransporter KCC2,\nis decreasing.<\/p>\n\n\n\n

When the Cl- concentration within the cell\nbecomes too high, the Cl- inflow mediated by GABA receptors switches to Cl-\nefflux, triggering an excitatory response (Hildebrand et al., 2016). [29]. As a\nresult, Brain-derived neurotrophic factor BDNF\ncan have an effect on the effect of the GABAergic machine further to regulating\nexcitatory transmission by way of lowering inhibition or maybe switching from\nexcitation to inhibition. <\/p>\n\n\n\n

Consequences showed that\npharmacological inhibition of 6GABAA receptors, a subunit of GABA receptors,\ndecreased the raised pain threshold in continual constriction damage (CCI)\nversion mice, suggesting that GABAergic disinhibition is likely to be a\nsizeable contributor to neuropathic ache 26<\/sup>.\nThrough the downstream signaling associate of TrkB, Fyn kinase,\nmicroglial-secreted BDNF can phosphorylate GluN2B 29 <\/sup>Furthermore, it\npromotes glutamate release with the aid of activating NMDA receptors in number\none afferent neurons’ presynaptic terminals 30<\/sup>. more recently, it’s\nbeen proven that neuropathic pain reasons lengthy-term potentiation in the\nspinal cord due to the fact BDNF, that’s produced with the aid of microglia,\nwill increase the number of synaptic terminals in number one sensory fibers\nwhich can be high quality for CGRP 31<\/sup>. The potential to regulate\nboth excitatory and inhibitory neurotransmission is furnished by BDNF. In\naddition to trigeminal nerve damage, extra situations would possibly motive\nmicroglia to end up active. Fractalkine is produced on the membrane surface of\nneurons by using the lysosomal cysteine protease cathepsin S, that’s secreted\nby means of microglia. Fractalkine binds to the CX3CR1 receptor, which is best\nexpressed in microglia, and keeps these cells in an activated country32 <\/sup>.\nThe extended launch of inflammatory cytokines by way of microglia consequences\nin painful infection. it is widely regularly occurring that microglia have a\nrole inside the improvement of neuropathic ache. The microglial activation\ninhibitor minocycline, however, has little effect on pain that is already gift.\nThis can be resulting from the section shift in glial activation that occurs\nafter nerve harm.<\/p>\n\n\n\n\n\n
\"\"<\/td>\nFigure 1: <\/strong>Following injury to the trigeminal nerve, the changes that take place in the TG, the wounded location, and the Vc\/C1-C2 region are shown below in the form of a schematic. <\/strong>

<\/p>\n

Click here to view Figure<\/a><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n

It is well knowledge that astrocytes may influence the physiological activity of neurons in the following way: the glutamine that is generated by astrocytes can be transformed into glutamate in the presynaptic terminal. Glutamate is a key component of excitatory neurotransmission. According to Allen and Eroglu (2017), adjacent astrocytes throughout the entire junction work together to coordinate their activity as neuronal assemblies 1<\/sup>. Carbenoxolone is a gap junction blocker, while methionine sulfoximine is a glutamine synthetase inhibitor. Both of these medications significantly reduce the nociceptive behaviour that is brought on by pulpitis and infraorbital nerve transection 33<\/sup>. The following are some examples of how the neurotransmitter D-serine, which is produced by astrocytes, is connected with orofacial pain: According to Zhou LJ et al.’s research from 2019, the co-agonist D-serine works on NMDA receptors to increase C-fiber-mediated long-time period potentiation 34 <\/sup>. Orofacial pain is caused by glial cells’ inappropriate manipulation of neuronal characteristic, which also helps to maintain its level of intensity (Figure 2).<\/p>\n\n\n\n\n\n
\"\"<\/td>\nFigure 2: <\/strong>After damage has been done to a peripheral nerve, microglia and astrocytes are shown to become activated inside the Vc. Microglia and astrocytes may be seen in the visual cortex of both normal rats and rats with IONI in the images. <\/strong>

<\/p>\n

Click here to view Figure<\/a><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n

When the primary afferent neurons of the\ntrigeminal nerve are compromised, such as when the inferior alveolar nerve,\nmental nerve, or infraorbital nerve is cut, satellite glial cells inside the TG\nbecome activated. Extra activation of microglial cells and astrocytes is\ndetected, leading to hyper-activation of Vc and C1-C2 nociceptive neurons 35<\/sup>.\nIn addition to IL-1, IL-1, and IL-6, other cytokines and bio-energetic\nchemicals have a role in regulating microglial activity in the central nervous\nsystem. Patients who were given minocycline reported less orofacial neuropathic\npain and a restoration of normal brain activity after partial infraorbital\nnerve ligation 35<\/sup>. As a result, minocycline may soon be used to\ntreat orofacial neuropathic pain. Research into treatment options for orofacial\nneuropathic pain should also concentrate on creating therapies with minimal\nadverse effects.<\/p>\n\n\n\n

Diagnosis of Orofacial Neuropathic Pain<\/strong><\/p>\n\n\n\n

In step with the worldwide class of\nOrofacial pain (ICOP), orofacial neuropathic ache is “Orofacial pain\nbecause of lesion or contamination of the cranial nerves”[36]<\/sup>.Orofacial\nneuropathic pain poses particular problems in assessment to neuropathic ache\ninside the spinal wire. The orofacial region’s anatomical limitations and\nassociated scientific speciality demarcations, according to the international\nHeadache Society, are a contributing element inside the problem 36<\/sup>.\nas an instance, it may be difficult to make a proper diagnosis and determine on\nthe exceptional direction of remedy due to the fact the symptoms of neuropathic\nache within the orofacial area regularly resemble the ones of odontogenic\ntoothache [36,37]<\/sup>. Many non-odontogenic toothaches are introduced on\nby way of the complexity of the orofacial vicinity, which includes numerous\nstructures innervated via the trigeminal machine, head, sinus, masticatory\nmuscle groups, temporomandibular joint, jaw, enamel, and gingiva 38<\/sup>.\nMoreover, it is difficult to degree orofacial discomfort due to the fact it’s\nmiles subjective. To avoid pointless dental treatment, it’s far important to\ndiscover the true supply of the ache.<\/p>\n\n\n\n

The mandibular nerve, the 0.33 department\nof the trigeminal nerve, is the web page of the most not unusual kind of TN. in\nthe enamel, paroxysmal ache is regularly felt and can be an illustration of\nendodontic pain and necessitate useless endodontic remedy 2<\/sup>.\nThe history of the affected person and the patient’s clarification in their\nsymptoms are used to make the TN analysis. As a result, with a view to make a\nclear prognosis, a lengthy verbal exchange with the affected person is\nrequired. TN pain is characterized by using brief\u2014up to 2 min long\u2014acute,\nabrupt, shooting ache bursts that seem electric surprise-like. Whether or not\nconsuming, brushing one’s enamel, talking, or using makeup, these may be\nslightly stimulated orofacially. In conventional TN, blood vessels at the brain\nstem’s root front region constantly squeeze the trigeminal nerve. Subsequently,\nto diagnose TN, investigations and in-intensity interviews are needed. A few\nexamples encompass the evaluation of the cranial nerves, mind MRIs, and brain\nmagnetic resonance angiography (MRA). One normal type of chronic neuropathic\npain is put up-annoying trigeminal neuropathy, though a few instances can be\nepisodic and ultimate anywhere from a couple of minutes to numerous days. The\norofacial place may be impacted with the aid of third molar extractions,\nimplants, root canal therapy, orthognathic surgical procedure, and facial\nfractures. The ache is generally defined as a consistent burning and\/or taking\npictures sensation on the injury web page or in the distal dermatome of the\ninjured nerve. Early on, odontogenic ache is generally fallacious for\nintra-oral submit-disturbing trigeminal neuropathic ache 39<\/sup><\/p>\n\n\n\n

On account of the whole trauma history and\nthe typical publish-worrying trigeminal neuropathic pain symptoms, a specific\ndiagnosis is likewise made. Therefore, as a way to diagnose submit-traumatic\ntrigeminal neuropathic ache, it’s miles critical to behavior chairside sensory\ntrying out, such as quantitative sensory testing (QST), and to be aware about\nthe patient’s particular scientific records 40,<\/sup> 41<\/sup>. Put up-demanding trigeminal neuropathic\npain is defined as “unilateral or bilateral facial or mouth pain following\nand prompted through trauma to the trigeminal nerve(s), with associated signs\nand symptoms and\/or scientific proof of trigeminal nerve dysfunction, and\npersisting or recurrent for greater than 3 months” 36<\/sup>. <\/p>\n\n\n\n

Trigeminal post herpetic neuralgia is some\nother not unusual example of persistent neuropathic ache. It\u2019s far a herpes\nzoster (HZ) sickness that developed from trigeminal neuropathic pain delivered\non by the virus. This pain is generally misdiagnosed as a toothache within the\nearly stages and outcomes in pointless dental remedy 42<\/sup>. No matter\nthe lesions healed after some months, the infection by HZ reasons a intense\ntrigeminal neuropathy. Typically, 10 to fifteen percent of HZ patients will\nexpand trigeminal post herpetic neuralgia. More than 50% of those over 60 go\nthrough with trigeminal post herpetic neuralgia.  Its scientific capabilities include allodynia,\nhyperalgesia to mechanical and thermal stimuli, and pain that is scorching,\ncapturing, or electric shock-like those functions are also present in\npost-worrying trigeminal neuropathic pain. As a result, to make the diagnosis\nof trigeminal post herpetic neuralgia, a whole affected person records and\nsensory evaluation are wished. Notwithstanding the rarity of these latter\nneuropathic lawsuits, a thorough analysis method is wanted36<\/sup>.<\/p>\n\n\n\n

Neuropathic pain outcomes in ectopic or\nextraterritorial pain while nerves within the spinal area and orofacial place\nare damaged. But, because dental pain is frequently confused for the referred\npain inside the orofacial location, useless and irreversible dental operations\nlike pulpotomies or teeth extractions are carried out. Even though the neuronal\nconvergence and sensitization hypotheses had been used to give an explanation\nfor referred pain, it’s miles hard to define all the events which might be\ninduced by way of referred pain43<\/sup>. As already indicated, the\nmechanism of referred ache has lately been attributed to a diffusion of\nmolecular and mobile changes in peripheral, imperative, neuronal, and\nnon-neuronal cells. Medicinal experiments the use of those cells’ inhibitors\nand modulators have produced a few encouraging outcomes, even though the tiers\nof efficacy are still inconsistent 30. <\/sup>As these medicines broaden,\nthe management of orofacial neuropathic ache and warding off beside the point\nremedy may also end up much less complicated for the practitioner.<\/p>\n\n\n\n

Clinical implication of trigeminal\nneuralgia:<\/strong><\/p>\n\n\n\n

The clinical aspect includes\nspontaneously pain experienced along the upper jaw or lower jaw assuming that\nit may due to dental abscess or cyst & going for the endodontic treatment\nor extraction. But when the pain persist even after the dental treatment then\nthey realized it is due to some other reason. The character of pain is\nintensely sharp, stabbing sporadic burning or shock like pain around the eyes\nlips nose jaw forehead & scalp.  This\npain runs in cyclic manner with frequent attacks occurring by weeks, months or\neven years. The pattern od pain typically begins with sensation electrical\nshock that culminates in an excruciating stabbing pain within 30 seconds\naccompanied facial twitch focusing at on point r spreading type affecting one\nface unilaterally. The triggering factor include: touching the skin, washing,\nshaving, brushing, smiling, talking, encountering a breeze of air, <\/p>\n\n\n\n

Differential diagnosis: there are few lesion which can show overlapping features similar to trigeminal neuralgia that includes cluster headaches, giant cell arteritis, dental pain, post herpetic neuralgia, sinus pain, ear infection, temporomandibular joint syndrome, glossopharyngeal neuralgia, eagle syndrome.<\/p>\n\n\n\n

Clinical Management of Pain in the\nOrofacial Region<\/strong><\/p>\n\n\n\n

In comparison to other neuropathic pain\nsyndromes, such as post-herpetic neuralgia, severe diabetic neuropathy, and\npainful spinal stressful neuropathy, which have a pharmaceutical response\ncharge of 20\u2013forty%, Painful traumatic trigeminal neuropathy (PTTN) is\nstated to have a low reaction rate of just 11%. However, PPTTN, trigeminal\nneuralgia, and PHTN are the three orofacial neuropathic pain conditions that\nare most often seen. PPTTN is caused by injury to the trigeminal nerve, which\nmay occur as a result of treatments such as pulp extirpation, apicectomy, the\nextraction of teeth, or general endodontic therapy. According to estimates\nprovided PPTTN develops in between 3 and 5% of all treatments of this kind 39<\/sup>.\nAccording to Okada-Ogawa et al. (2015), PPTTN typically results in a searing\npain that is localised to one side of the body and lasts for an extended period\nof time close to or on the location of the injury. This pain is frequently\nfollowed by an acute, stabbing sensation26<\/sup>. Loss of sensory\nperception is another possibility. After a period of time, it becomes clear\nthat the central nervous system is also involved, despite the fact that at\nfirst it may seem that only the peripheral nervous system is impacted. It is\npossible to be preferred to manage topical and\/or systemic treatment to the\nperipheral, vital, or both terrified structures in order to control this\nproblem. This is something that may be done.<\/p>\n\n\n\n

Systemic Pharmacotherapy<\/strong><\/p>\n\n\n\n

Professional associations from all around\nthe world, such as those for your area, have posted scientific coaching\nrecommendations on the usage of pharmaceuticals to treat neuropathic ache. The\nmaximum often recommended centrally focused analgesics include gabapentin,\npregabalin, venlafaxine, tricyclic antidepressants (TCAs; e.g., amitriptyline\nand nortriptyline), and serotonin-norepinephrine reuptake inhibitors (SNRIs;\ne.g., duloxetine and venlafaxine)46. <\/sup>The primary PPTTN drugs\nutilized were the latter an aggregate of gabapentin or pregabalin plus\nduloxetine or amitriptyline must be used as an alternate remedy for PPTTN. If\nthe primary method fails, opioids and opioid cocktail combos is probably a\npossible backup. Pregabalin and gabapentin are each anticonvulsants. These two\ntablets block the discharge of excitatory neurotransmitters like glutamate and\nSP by cooperating with the voltage-gated calcium channel’s subunit 2.\nPregabalin and gabapentin are clinically effective for treating diabetic\nneuropathy, in addition to chronic ache and numbness related to PHTN 47<\/sup>.\nIn massive scientific research related to PHTN patients, pregabalin and\ngabapentin proven considerable efficacy on PHTN ache; this analgesic impact is\nequivalent to that observed in studies the usage of antidepressants. <\/p>\n\n\n\n

Mirogabalin, a these days advanced\ngabapentinoid, is a strong and particular 2 ligand. It\u2019s been permitted in\nJapan for the treatment of painful diabetic peripheral neuropathy, PHTN, in\naddition to other peripheral neuropathic symptoms 48,49 <\/sup>. The\nnociceptive afferent input to the medullary dorsal horn can be immediately\ndecreased or removed due to mirogabalin’s results on ectopic afferent pastime.\nIn keeping with a latest have a look at, PPTTN sufferers’ ache-inhibitory\nmachine gradually became less attentive to medicine 50. <\/sup> As an end result, patients with PPTTN ought to\nbe controlled with a focus on insufficient inhibitory pain law. It\u2019s far\nbelieved that TCAs and SNRIs prevent norepinephrine and serotonin from\nreuptaking 50<\/sup><\/p>\n\n\n\n

Carbamazepine and oxcarbazepine are often\nrecommended as the first-line treatment for trigeminal neuralgia; however, a\ncomprehensive study found that ninety percent of people who suffer from\ntrigeminal neuralgia report much reduced discomfort when using these\nmedications. According to Moore et al. (2019), the secondary treatment for classic\ntrigeminal neuralgia includes the medications baclofen, lamotrigine,\npregabalin, and gabapentin 51<\/sup>. In\nmodern day treatment, it is recommended to make use of intravenous\nfosphenytoin, topical or injectable sumatriptan, or intravenous lidocaine in\norder to boost the efficacy of oral anticonvulsants and put a halt to an acute\nepisode 51<\/sup>. In order to reduce the\nrisk of developing orofacial neuropathic pain, a preoperative treatment known\nas pre-emptive analgesia may be administered. This treatment, in general, aims\nto reduce the initial damage-induced afferent volley and significant\nsensitization while also lowering the formation of anti-inflammatory mediators.\nThis is accomplished through the utilisation of local anaesthetic blocks during\ninvasive dentistry or oral surgical operation procedures 52<\/sup>. The relative timing of anaesthetic\ntreatments is a key consideration in preemptive or preventative analgesia,\nwhich is also known as preventive analgesia. It lessens the side effects of\nperipheral nociceptive transduction brought on by painful stimuli before,\nduring, and\/or after surgical procedures 53<\/sup>.\nClinicians may want to consider making use of local anaesthetic for invasive\ndental operations in addition to making use of preventative analgesics and\/or\nanti-inflammatory medications in order to minimise the amount of postoperative\npain experienced by patients in the patient setting.<\/p>\n\n\n\n

Majority of the patients fair\nenough with the pharmacology treatment\/drugs like the carbamazepine &\noxcarbazepine which forms the first line treatment options followed by  lamotrigine & baclofen encompassing the\nsecond line of drugs along with adjuvant drug support of topiramate,\nlevetiracetam, gabapentin, pregabalin. As the field of science has explored\n&advanced for the latest treatment options include microvascular\ndecompression, gamma knife radiosurgery, percutaneous rhizotomies variable\nbased on the evidences & guidelines 54<\/sup>. <\/p>\n\n\n\n

Conclusion <\/strong><\/p>\n\n\n\n

As a consequence of injury to the\ntrigeminal nerve, astrocytes, microglial cells, and astroglial cells become\nactivated, and macrophages accumulate. The compounds that may be created by\nemploying these non-neuronal cells and then released play a part in enhancing\nthe unpleasant neuronal attention that is being experience. The findings of\nthis study may already be used as a valuable resource in the diagnosis and\ntreatment of individuals with orofacial neuropathic pain; however, more\nresearch will need to delve at more specific non-neuronal cellular\ncharacteristic processes in order to fully understand these conditions.<\/p>\n\n\n\n

Conflict\nof Interest<\/strong><\/p>\n\n\n\n

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<\/p>\n\n\n\n

References<\/strong><\/p>\n\n\n\n

  1. Allen NJ, Eroglu C. Cell Biology of Astrocyte-Synapse Interactions. Neuron. 2017 Nov 1; 96(3):697-708. Doi: 10.1016\/j.neuron.2017.09.056. PMID: 29096081; PMCID: PMC5687890.
    CrossRef<\/a><\/li>
  2. Antonaci, F., Arceri, S., Rakusa, M. et al. Pitfals in recognition and management of trigeminal neuralgia. J Headache Pain 21, 82 (2020). https:\/\/doi.org\/10.1186\/s10194-020-01149-8
    CrossRef <\/a><\/li>
  3. Asano S, Hayashi Y, Iwata K, Okada-Ogawa A, Hitomi S, Shibuta I, Imamura Y, Shinoda M. Microglia-Astrocyte Communication via C1q Contributes to Orofacial Neuropathic Pain Associated with Infraorbital Nerve Injury. Int J Mol Sci. 2020 Sep 17; 21(18):6834. Doi: 10.3390\/ijms21186834. PMID: 32957694; PMCID: PMC7560139.
     CrossRef <\/a><\/li>
  4. Baad-Hansen L, Benoliel R. Neuropathic orofacial pain: Facts and fiction. Cephalalgia. 2017 Jun; 37(7):670-679. Doi: 10.1177\/0333102417706310. Epub 2017 Apr 12. PMID: 28403646.
     CrossRef <\/a><\/li>
  5. Batbold D, Shinoda M, Honda K, Furukawa A, Koizumi M, Akasaka R, Yamaguchi S, Iwata K. Macrophages in trigeminal ganglion contribute to ectopic mechanical hypersensitivity following inferior alveolar nerve injury in rats. J Neuroinflammation. 2017 Dec 16;14(1):249. doi: 10.1186\/s12974-017-1022-3. PMID: 29246259; PMCID: PMC5732495.
     CrossRef <\/a><\/li>
  6. Bates, D., Schultheis, B. C., Hanes, M. C., Jolly, S. M., Chakravarthy, K. V., Deer, T. R., et al. A comprehensive algorithm for management of neuropathic pain. Pain Med. (2019).  20(Suppl. 1), S2\u2013S12. Doi: 10.1093\/pm\/pnz075.
    CrossRef <\/a><\/li>
  7. Bayat A, Burbelo PD, Browne SK, Quinlivan M, Martinez B, Holland SM, Buvanendran A, Kroin JS, Mannes AJ, Breuer J, Cohen JI, Iadarola MJ. Anti-cytokine autoantibodies in post herpetic neuralgia. J Transl Med. 2015 Oct 20; 13:333. Doi: 10.1186\/s12967-015-0695-6. PMID: 26482341; PMCID: PMC4617715.
     CrossRef <\/a><\/li>
  8. Chen MJ, Kress B, Han X, Moll K, Peng W, Ji RR, Nedergaard M. Astrocytic CX43 hemichannels and gap junctions play a crucial role in development of chronic neuropathic pain following spinal cord injury. Glia. 2012 Nov; 60(11):1660-70. Doi: 10.1002\/glia.22384. Epub 2012 Aug 1. PMID: 22951907; PMCID: PMC3604747.
     CrossRef <\/a><\/li>
  9. Koichi Iwata, Mamoru Takeda, Seog Bae Oh, Masamichi Shinoda Neurophysiology of Orofacial Pain Contemporary Oral Medicine, 2017. ISBN : 978-3-319-28100-1
     CrossRef <\/a><\/li>
  10. Shinoda M, Imamura Y, Hayashi Y, Noma N, Okada-Ogawa A, Hitomi S, Iwata K. Orofacial Neuropathic Pain-Basic Research and Their Clinical Relevancies. Front Mol Neurosci. 2021 Jul 6; 14:691396. Doi: 10.3389\/fnmol.2021.691396. PMID: 34295221; PMCID: PMC8291146.
    CrossRef <\/a><\/li>
  11. Peng Q, Wang Y, Li M, Yuan D, Xu M, Li C, Gong Z, Jiao R, Liu L. cGMP-Dependent Protein Kinase Encoded by foraging Regulates Motor Axon Guidance in Drosophila by Suppressing Lola Function. J Neurosci. 2016 Apr 20;36(16):4635-46. doi: 10.1523\/JNEUROSCI.3726-15.2016. PMID: 27098704; PMCID: PMC6601827.
    CrossRef <\/a><\/li>
  12. Chu LW, Cheng KI, Chen JY, Cheng YC, Chang YC, Yeh JL, Hsu JH, Dai ZK, Wu BN. Loganin prevents chronic constriction injury-provoked neuropathic pain by reducing TNF-\u03b1\/IL-1\u03b2-mediated NF-\u03baB activation and Schwann cell demyelination. Phytomedicine. 2020 Feb; 67:153166. Doi: 10.1016\/j.phymed.2019.153166. Epub 2019 Dec 30. PMID: 31955133.
     CrossRef <\/a><\/li>
  13. Andrea Leo, Giacomo Handjaras, Matteo Bianchi, Hamal Marino, Marco Gabiccini, Andrea Guidi, Enzo Pasquale Scilingo, Pietro Pietrini, Antonio Bicchi, Marco Santello, Emiliano Ricciardi (2016) A synergy-based hand control is encoded in human motor cortical areaseLife 5:e13420. https:\/\/doi.org\/10.7554\/eLife.13420
     CrossRef <\/a><\/li>
  14. Shinoda K, Luijten IH, Hasegawa Y, Hong H, Sonne SB, Kim M, Xue R, Chondronikola M, Cypess AM, Tseng YH, Nedergaard J, Sidossis LS, Kajimura S. Genetic and functional characterization of clonally derived adult human brown adipocytes. Nat Med. 2015 Apr;21(4):389-94. doi: 10.1038\/nm.3819. Epub 2015 Mar 16. PMID: 25774848; PMCID: PMC4427356.
     CrossRef <\/a><\/li>
  15. Laura Minnema, Ankita Gupta, Santosh K. Mishra, B. Duncan X. Lascelles. Investigating the role of artemin & its cognitive receptor, GFR3, in osteoarthritis pain. Front. Neurosci, 27 January 2022 sec neuropharmacology vol 16-2022.  https:\/\/doi.org\/10.3389\/fnins.2022.738976
    CrossRef <\/a><\/li>
  16. Bailes J, Soloviev M. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports. Biomolecules. 2021 Feb 4; 11(2):217. Doi: 10.3390\/biom11020217. PMID: 33557137; PMCID: PMC7913862.
     CrossRef <\/a><\/li>
  17. Shinoda N, Hanawa N, Chihara T, Koto A, Miura M. Dronc-independent basal executioner caspase activity sustains Drosophila imaginal tissue growth. Proc Natl Acad Sci U S A. 2019 Oct 8; 116(41):20539-20544. Doi: 10.1073\/pnas.1904647116. Epub 2019 Sep 23. PMID: 31548372; PMCID: PMC6789915.
    CrossRef <\/a><\/li>
  18. Iwata K, Sessle BJ. The Evolution of Neuroscience as a Research Field Relevant to Dentistry. J Dent Res. 2019 Dec; 98(13):1407-1417. Doi: 10.1177\/0022034519875724. PMID: 31746682.
    CrossRef <\/a><\/li>
  19. Profiling sensory neuron microenvironment after peripheral and central axon injury reveals key pathways for neural repair.Avraham,Feng R,Ewan EE, Rustenhoven J, Zhao G, Cavalli V. Elife, 29 Sep 2021, 10:e68457 DOI: 10.7554\/elife.68457
    CrossRef <\/a><\/li>
  20. K.M. Hargreaves Review Orofacial pain \/ PAIN 152 (2011) S25\u2013S32. 0304-3959\/$36.00 2011 International Association for the Study of Pain. Published by Elsevier B.V. doi:10.1016\/j.pain.2010.12.024
     CrossRef <\/a><\/li>
  21. Liu, Y., Lin, W., Liu, C. et al. Memory consolidation reconfigures neural pathways involved in the suppression of emotional memories. Nat Commun 7, 13375 (2016). https:\/\/doi.org\/10.1038\/ncomms13375
    CrossRef <\/a><\/li>
  22. Hansson, E., Ski\u00f6ldebrand, E. Coupled cell networks are target cells of inflammation, which can spread between different body organs and develop into systemic chronic inflammation. J Inflamm 12, 44 (2015). https:\/\/doi.org\/10.1186\/s12950-015-0091-2
     CrossRef <\/a><\/li>
  23. M\u00f6ckel L, Gerhard A, Mohr M, Armbrust CI, M\u00f6ckel C. Prevalence of pain, analgesic self-medication and mental health in German pre-hospital emergency medical service personnel: a nationwide survey pilot-study. Int Arch Occup Environ Health. 2021 Nov; 94(8):1975-1982. doi: 10.1007\/s00420-021-01730-x. Epub 2021 Jun 7. PMID: 34097107; PMCID: PMC8180540.
    CrossRef <\/a><\/li>
  24. Liang H, Hu H, Shan D, et al. CGRP Modulates Orofacial Pain through Mediating Neuron-Glia Crosstalk. Journal of Dental Research. 2021; 100(1):98-105. doi:10.1177\/0022034520950296
    CrossRef <\/a><\/li>
  25. Dubner R, Ren K. Brainstem mechanisms of persistent pain following injury. J Orofac Pain. 2004 Fall; 18(4):299-305. PMID: 15636012.<\/li>
  26. Akiko OkadaOgawa a b, Yuka Nakaya a, Yoshiki Imamura a b, Masayuki Kobayashi c, Masamichi Shinoda b d, Kozue Kita b, Barry J. Sessle e, Koichi Iwata  Involvement of medullary GABAergic system in extraterritorial neuropathic pain mechanisms associated with inferior alveolar nerve transection b Experimental NeurologyVolume 267, May 2015, Pages 42-52. https:\/\/doi.org\/10.1016\/j.expneurol. 2015.02.030
     CrossRef <\/a><\/li>
  27. Guo, W., Wang, H., Watanabe, M., Shimizu, K., Zou, S., LaGraize, S. C., et al. (2007). Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J. Neurosci. 27, 6006\u20136018. doi: 10.1523\/JNEUROSCI.0176-07.2007
    CrossRef <\/a><\/li>
  28. Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J Neurosci. 2008 May 14; 28(20):5189-94. Doi: 10.1523\/JNEUROSCI.3338-07.2008. PMID: 18480275; PMCID: PMC2408767.
    CrossRef <\/a><\/li>
  29. Hildebrand, M. E., Xu, J., Dedek, A., Li, Y., Sengar, A. S., Beggs, S., et al. (2016). Potentiation of synaptic GluN2B NMDAR currents by fyn kinase ss gated through BDNF-mediated disinhibition in spinal pain processing. Cell Rep. 17, 2753\u20132765. Doi: 10.1016\/j.celrep.2016.11.024.
     CrossRef <\/a><\/li>
  30. Zhou M, Chen N, Tian J, Zeng J, Zhang Y, Zhang X, Guo J, Sun J, Li Y, Guo A, Li Y. Suppression of GABAergic neurons through D2-like receptor secures efficient conditioning in Drosophila aversive olfactory learning. Proc Natl Acad Sci U S A. 2019 Mar 12; 116(11):5118-5125. Doi: 10.1073\/pnas.1812342116. Epub 2019 Feb 22. PMID: 30796183; PMCID: PMC6421402.
     CrossRef <\/a><\/li>
  31. Clark, A. K., Yip, P. K., Grist, J., Gentry, C., Staniland, A. A., Marchand, F., et al. (2007). Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc. Natl. Acad. Sci. U.S.A 104, 10655\u201310660. Doi: 10.1073\/pnas.0610811104.
    CrossRef <\/a><\/li>
  32. Tsuboi Y, Iwata K, Dostrovsky JO, Chiang CY, Sessle BJ, Hu JW. Modulation of astroglial glutamine synthetase activity affects nociceptive behavior and central sensitization of medullary dorsal horn nociceptive neurons in a rat model of chronic pulpitis. Eur J Neurosci. 2011 Jul; 34(2):292-302. Doi: 10.1111\/j.1460-9568.2011.07747.x. Epub 2011 Jun 27. PMID: 21707791.
    CrossRef <\/a><\/li>
  33. Zhou LJ, Peng J, Xu YN, Zeng WJ, Zhang J, Wei X, Mai CL, Lin ZJ, Liu Y, Murugan M, Eyo UB, Umpierre AD, Xin WJ, Chen T, Li M, Wang H, Richardson JR, Tan Z, Liu XG, Wu LJ. Microglia Are Indispensable for Synaptic Plasticity in the Spinal Dorsal Horn and Chronic Pain. Cell Rep. 2019 Jun 25; 27(13):3844-3859.e6. Doi: 10.1016\/j.celrep. 2019.05.087. PMID: 31242418; PMCID: PMC7060767.
     CrossRef <\/a><\/li>
  34. Iwata K, Sessle BJ. The Evolution of Neuroscience as a Research Field Relevant to Dentistry. J Dent Res. 2019 Dec; 98(13):1407-1417. Doi: 10.1177\/0022034519875724. PMID: 31746682.
     CrossRef <\/a><\/li>
  35. ICOP (2020). International classification of orofacial pain, 1st edition (ICOP). Cephalalgia 40, 129\u2013221. doi: 10.1177\/0333102419893823
    CrossRef <\/a><\/li>
  36. Christoforou J. Neuropathic Orofacial Pain. Dent Clin North Am. 2018 Oct; 62(4):565-584. Doi: 10.1016\/j.cden.2018.05.005. Epub 2018 Jul 31. PMID: 30189983.
     CrossRef <\/a><\/li>
  37. Christoforou, J., Balasubramaniam, R. & Klasser, G.D. Neuropathic Orofacial Pain. Curr Oral Health Rep 2, 148\u2013157 (2015). https:\/\/doi.org\/10.1007\/s40496-015-0052-0
     CrossRef <\/a><\/li>
  38. Sara Zamiri,1Mohammad Jafar Shaterzadeh Yazdi,2Elham Maraghi,3and Ismail Ebrahimi Takamjani The E\ufb00ectiveness of Classi\ufb01cation-Speci\ufb01c Physical Therapy for People with Low Back pain Within Dominant Movement-Based Schemes: A Systematic Review Iran Red Crescent Med J. 2016 December; 18(12):e41959. Published online 2016 December 4. doi: 10.5812\/ircmj.41959.
    CrossRef <\/a><\/li>
  39. Baad-Hansen L, Benoliel R. Neuropathic orofacial pain: Facts and fiction. Cephalalgia. 2017 Jun; 37(7):670-679. Doi: 10.1177\/0333102417706310. Epub 2017 Apr 12. PMID: 28403646.
     CrossRef <\/a><\/li>
  40. Devine, M., Hirani, M., Durham, J., Nixdorf, D. R., and Renton, T. (2018). Identifying criteria for diagnosis of post-traumatic pain and altered sensation of the maxillary and mandibular branches of the trigeminal nerve: a systematic review. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 125, 526\u2013540. Doi: 10.1016\/j.oooo.2017.12.020.
    CrossRef <\/a><\/li>
  41. Rotpenpian N, Yakkaphan P. Review of Literatures: Physiology of Orofacial Pain in Dentistry. eNeuro. 2021 Apr 27; 8(2):ENEURO.0535-20.2021. Doi: 10.1523\/ENEURO.0535-20.2021. PMID: 33820801; PMCID: PMC8086974.
     CrossRef <\/a><\/li>
  42. Paquin S, Lacourse E, Brendgen M, Vitaro F, Dionne G, Tremblay RE, Boivin M. Heterogeneity in the development of proactive and reactive aggression in childhood: Common and specific genetic – environmental factors. PLoS One. 2017 Dec 6; 12(12):e0188730. Doi: 10.1371\/journal.pone.0188730. PMID: 29211810; PMCID: PMC5718601.
    CrossRef <\/a><\/li>
  43. Markman JD, Gewandter JS, Frazer ME. Comparison of a Pain Tolerability Question with the Numeric Rating Scale for Assessment of Self-reported Chronic Pain. JAMA Netw Open.<\/em> 2020; 3(4):e203155. doi:10.1001\/jamanetworkopen.2020.3155
     CrossRef<\/a> <\/li>
  44. Chen, W., Walwyn, W., Ennes, H. S., Kim, H., McRoberts, J. A., and Marvizon, J. C. (2014). BDNF released during neuropathic pain potentiates NMDA receptors in primary afferent terminals. Eur. J. Neurosci. 39, 1439\u20131454. Doi: 10.1111\/ejn.12516.
    CrossRef <\/a><\/li>
  45. Haviv, Y., Zadik, Y., Sharav, Y., and Benoliel, R. (2014). Painful traumatic trigeminal neuropathy: an open study on the pharmacotherapeutic response to stepped treatment. J. Oral Facial Pain Headache 28, 52\u201360. doi: 10.11607\/jot.1154
     CrossRef <\/a><\/li>
  46. Derry, S., Wiffen, P. J., Moore, R. A., and Quinlan, J. (2014). Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst. Rev. 2014:CD010958. Doi: 10.1002\/14651858.CD010958.pub2.
    CrossRef <\/a><\/li>
  47. Dieb, W., and Hafidi, A. (2013). Astrocytes are involved in trigeminal dynamic mechanical allodynia: potential role of D-serine. J. Dent. Res. 92, 808\u2013813. doi: 10.1177\/0022034513498898.
    CrossRef <\/a><\/li>
  48. Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicenter, randomized, open-label, phase 3 trial. Lancet Oncol. 2019 Nov; 20(11):1506-1517. Doi: 10.1016\/S1470-2045(19)30626-6. Epub 2019 Sep 30. Erratum in: Lancet Oncol. 2019 Nov; 20(11):e613. PMID: 31582355.
    CrossRef <\/a><\/li>
  49. Nasri-Heir C, Zagury JG, Thomas D, Ananthan S. Burning mouth syndrome: Current concepts. J Indian Prosthodont Soc. 2015 Oct-Dec; 15(4):300-7. Doi: 10.4103\/0972-4052.171823. PMID: 26929531; PMCID: PMC4762357.
     CrossRef <\/a><\/li>
  50. Olga Korczeniewska,Junad Khan,Eli Eliav,Rafael Benoliel. Molecular Mechanisms of Painful Traumatic Trigeminal Neuropathy \u2013 Evidence from Animal Research and Clinical Correlate June 2020 Journal of Oral Pathology and Medicine 49(6) DOI:10.1111\/jop.13078
     CrossRef <\/a><\/li>
  51. Moore DJ, Meints SM, Lazaridou A, Johnson D, Franceschelli O, Cornelius M, Schreiber K, Edwards RR. The Effect of Induced and Chronic Pain on Attention. J Pain. 2019 Nov; 20(11):1353-1361. Doi: 10.1016\/j.jpain.2019.05.004. Epub 2019 May 9. PMID: 31077797.
     CrossRef <\/a><\/li>
  52. Aldington D, Eccleston C. Evidence-Based Pain Management: Building on the Foundations of Cochrane Systematic Reviews. Am J Public Health. 2019 Jan; 109(1):46-49. Doi: 10.2105\/AJPH.2018.304745. Epub 2018 Nov 29. PMID: 30495991; PMCID: PMC6301419.
     CrossRef <\/a><\/li>
  53. Korczeniewska OA, James MH, Eliav T, Katzmann Rider G, Mehr JB, Affendi H, Aston-Jones G, Benoliel R. Chemogenetic inhibition of trigeminal ganglion neurons attenuates behavioural and neural pain responses in a model of trigeminal neuropathic pain. Eur J Pain. 2022 Mar; 26(3):634-647. Doi: 10.1002\/ejp.1887. Epub 2021 Dec 6. PMID: 34767278; PMCID: PMC8847328.
     CrossRef <\/a><\/li>
  54. Al-Quliti KW. Update on neuropathic pain treatment for trigeminal neuralgia. The pharmacological and surgical options. Neurosciences (Riyadh). 2015 Apr;20(2):107-14. doi: 10.17712\/nsj.2015.2.20140501. PMID: 25864062; PMCID: PMC4727618.
    CrossRef <\/a><\/li><\/ol>\n\n\n\n

    Abbreviations<\/strong><\/p>\n\n\n\n

    AMPA,\nalpha amino-3-hydroxy-5-methyl-4-isoxazole-propionate; BDNF, brain-derived\nneurotrophic factor; CCI, Chronic Constriction Injury; CCL2, the chemokine C-C\nmotif ligand 2; C1-C2, the upper cervical spinal cord; Cx43, Connexin 43; HZ,\nherpes zoster; IASP, International Association for the Study of Pain; IGF-1,\ninsulin-like growth factor-1; IL, interleukin; KCC2, K+-Cl\u2013 cotransporter;\nMCP-1, monocyte chemoattractant protein-1; MRA, magnetic resonance angiography;\nMRI, magnetic resonance imaging; MT, medial thalamic nuclei; Nav1.8,\nvoltage-gated sodium channels 1.8; NMDA, N-methyl -D-aspartate; PBN,\nparabrachial nucleus; QST, quantitative sensory testing; sEPSCs, spontaneous\nexcitatory postsynaptic currents; sIPSCs, spontaneous inhibitory postsynaptic\ncurrents; SNRIs, serotonin-norepinephrine reuptake inhibitors; SP, Substance P;\nPHTN, Post herpetic trigeminal neuralgia; PPTTN, peripheral, painful, traumatic\ntrigeminal neuropathy; TCAs, tricyclic antidepressants; TG, trigeminal\nganglion; TN, trigeminal neuralgia; TNFR, TNF receptor; TNF\u03b1, tumor necrosis\nfactor alpha; TrkB, tropomyosin-related kinase B; Vc, trigeminal spinal\nsubnucleus caudalis.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Introduction When a peripheral nerve is destroyed, injured nerve fibres […]<\/p>\n","protected":false},"author":15,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[107],"tags":[],"class_list":["post-49848","post","type-post","status-publish","format-standard","hentry","category-vol16no2"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/49848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=49848"}],"version-history":[{"count":5,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/49848\/revisions"}],"predecessor-version":[{"id":50185,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/49848\/revisions\/50185"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=49848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=49848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=49848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}